Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein

Vaccine

Volumn 27, Issue 48, 2009, Pages 6799-6806

  Georgousakis, Melina M ^a   Hofmann, Andreas ^b   Batzloff, Michael R ^a   McMillan, David J ^a,b   Sriprakash, Kadaba S ^b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

helix; Fusion protein; Peptide; Streptococcus pyogenes; Vaccine

Indexed keywords

ANTIGEN; EPITOPE; H12 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G; J14H12; JJ0H12; M PROTEIN; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CHIMERA; CIRCULAR DICHROISM; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GENE SEQUENCE; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN SECONDARY STRUCTURE; STREPTOCOCCUS GROUP A;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CROSS REACTIONS; EPITOPES, B-LYMPHOCYTE; FEMALE; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 70350574651     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.049     Document Type: Article

References (37)

1. Carapetis J.R., Steer A.C., Mulholland E.K., and Weber M. The global burden of group A streptococcal diseases. Lancet Infectious Diseases 5 11 (2005) 685-694
2. Currie B.J. Group A streptococcal infections of the skin: molecular advances but limited therapeutic progress. Current Opinion in Infectious Diseases 19 2 (2006) 132-138
3. Bisno A.L. Acute pharyngitis: etiology and diagnosis. Pediatrics 97 6 (1996) 949-954
4. Hayman W.A., Brandt E.R., Relf W.A., Cooper J., Saul A., and Good M.F. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. International Immunology 9 11 (1997) 1723-1733
5. Relf W.A., Cooper J., Brandt E.R., Hayman W.A., Anders R.F., Pruksakorn S., et al. Mapping a conserved conformational epitope from the M protein of group A streptococci. Peptide Research 9 January-February (1) (1996) 12-20
6. Yoonim N., Olive C., Pruksachatkunakorn C., and Pruksakorn S. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population. BMC Microbiology (2006) 6
7. Batzloff M.R., Yan H., Davies M.R., Hartas J., Lowell G.H., White G., et al. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. Journal of Infectious Diseases 192 8 (2005 Oct 15) 1450-1455
8. Olive C., Sun H.K., Ho M.F., Dyer J., Horvath A., Toth I., et al. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. Journal of Infectious Diseases 194 3 (2006) 316-324
9. Brandt E.R., Hayman W.A., Currie B., Pruksakorn S., and Good M.F. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine 15 16 (1997) 1805-1812
10. Cleary P.P., Matsuka Y.V., Huynh T., Lam H., and Olmsted S.B. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine 22 31-32 (2004 Oct 22) 4332-4341
11. Schulze K., Medina E., Chhatwal G.S., and Guzman C.A. Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein. Vaccine 21 17-18 (2003 May 16) 1958-1964
12. Kreikemeyer B., Martin D.R., and Chhatwal G.S. SfbII protein, a fibronectin binding surface protein of group A streptococci, is a serum opacity factor with high serotype-specific apolipoproteinase activity. FEMS Microbiology Letters 178 2 (1999 Sep 15) 305-311
13. Kawabata S., Kunitomo E., Terao Y., Nakagawa I., Kikuchi K., Totsuka K-i, et al. Systemic and Mucosal Immunizations with Fibronectin-Binding Protein FBP54 Induce Protective Immune Responses against Streptococcus pyogenes Challenge in Mice. Infection and Immunity 69 2 (2001 February 1) 924-930
14. Courtney H.S., Hasty D.L., and Dale J.B. Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infection and Immunity 71 9 (2003) 5097-5103
15. Delvecchio A., Currie B.J., McArthur J.D., Walker M.J., and Sriprakash K.S. Streptococcus pyogenes prtFII, but not sfbI, sfbII or fbp54, is represented more frequently among invasive-disease isolates of tropical Australia. Epidemiology and Infection 128 3 (2002) 391-396
16. Edwards M.L., Fagan P.K., Towers R.J., Currie B.J., and Sriprakash K.S. Inhibition of Streptococcus pyogenes adherence to HaCaT cells by a peptide corresponding to the streptococcal fibronectin-binding protein, SfbI, is strain dependent. Microbes and Infection 6 10 (2004) 926-928
17. Molinari G., and Chhatwal G.S. Role played by the fibronectin-binding protein SfbI (protein F1) of Streptococcus pyogenes in bacterial internalization by epithelial cells. Journal of Infectious Diseases 179 4 (1999) 1049-1050
18. Talay S.R., Zock A., Rohde M., Molinari G., Oggioni M., Pozzi G., et al. Co-operative binding of human fibronectin to SfbI protein triggers streptococcal invasion into respiratory epithelial cells. Cellular Microbiology 2 6 (2000) 521-535
19. Molinari G., Talay S.R., ValentinWeigand P., Rohde M., and Chhatwal G.S. The fibronectin-binding protein of Streptococcus pyogenes, sfbI, is involved in the internalization of group A streptococci by epithelial cells. Infection and Immunity 65 4 (1997) 1357-1363
20. Molinari G., and Chhatwal G.S. Invasion and survival of Streptococcus pyogenes in eukaryotic cells correlates with the source of the clinical isolates. Journal of Infectious Diseases 177 6 (1998) 1600-1607
21. Guzman C.A., Talay S.R., Molinari G., Medina E., and Chhatwal G.S. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin binding protein SfbI. Journal of Infectious Diseases 179 4 (1999) 901-906
22. Schulze K., and Guzman C.A. Identification of the domains of the fibronectin-binding protein I of Streptococcus pyogenes responsible for adjuvanticity. FEMS Immunology and Medical Microbiology 37 2-3 (2003 Jul 15) 173-177
23. Batzloff M.R., Hayman W.A., Davies M.R., Zeng M., Pruksakorn S., Brandt E.R., et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: Contribution of J8-and diphtheria toxoid-specific antibodies to protection. Journal of Infectious Diseases 187 10 (2003 May 15) 1598-1608
24. In: Sambrook J., and Russel D.W. (Eds). Molecular cloning: A laboratory manual. 3rd ed. (2001), Cold Spring Harbour Laboratory Press, New York
25. Sulkowski E. Purification of Proteins by Imac. Trends in Biotechnology 3 1 (1985) 1-7
26. Hoffman A. ACDP - a Java application for data processing and analysis of protein circular dichroism spectra. Journal of Applied Chrystallography 42 (2009) 137-139
27. Medaglini D., Pozzi G., King T.P., Fischetti V.A., and Mucosal. Systemic Immune-Responses to a Recombinant Protein Expressed on the Surface of the Oral Commensal Bacterium Streptococcus-Gordonii after Oral Colonization. Proceedings of the National Academy of Sciences of the United States of America 92 15 (1995 Jul 18) 6868-6872
28. Burkhard P., Stetefeld J., and Strelkov S.V. Coiled coils: a highly versatile protein folding motif. Trends in Cell Biology 11 2 (2001) 82-88
29. Lupas A. Prediction and analysis of coiled-coil structures. Computer Methods for Macromolecular Sequence Analysis (1996) 513-525
30. Fischetti V.A., Manjula B.N., Flicker P.F., Cohen C., and Phillips G.N. The alpha-helical coiled-coil structure of streptococcal M-protein. Federation Proceedings 40 6 (1981) 1845-
31. Buck M. Trifluoroethanol and colleagues: cosolvents come of age. Recent studies with peptides and proteins. Quarterly Reviews of Biophysics 31 3 (1998) 297-355
32. Caparon M.G., Geist R.T., Perezcasal J., and Scott J.R. Environmental-Regulation of Virulence in Group a Streptococci - Transcription of the Gene Encoding M Protein Is Stimulated by Carbon-Dioxide. Journal of Bacteriology 174 17 (1992) 5693-5701
33. Gubbe K., Misselwitz R., Welfle K., Reichardt W., Schmidt K.H., and Welfle H. C repeats of the streptococcal M1 protein achieve the human serum albumin binding ability by flanking regions which stabilize the coiled-coil conformation. Biochemistry 36 26 (1997 Jul 1) 8107-8113
34. Fenderson P.G., Fischetti V.A., and Cunningham M.W. Tropomyosin shares immunologic epitopes with group A streptococcal M proteins. Journal of Immunology 142 7 (1989 Apr 1) 2475-2481
35. Gruber M., and Lupas A.N. Historical review: Another 50th anniversary - new periodicities in coiled coils. Trends in Biochemical Sciences 28 12 (2003) 679-685
36. Batzloff M., Yan H., Davies M., Hartas J., and Good M. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian Journal of Medical Research 119 Suppl (2004) 104-107
37. McNamara C., Zinkernagel A.S., Macheboeuf P., Cunningham M.W., Nizet V., and Ghosh P. Coiled-coil irregularities and instabilities in group A Streptococcus M1 are required for virulence. Science 319 5868 (2008) 1405-1408